Related Experiment Videos
Intervention in acute myocardial infarction
Insights
Early reperfusion therapy is crucial for reducing myocardial infarction. Prompt treatment, ideally within 3-5 hours, improves outcomes by restoring oxygen supply and minimizing heart muscle damage.
Area of Science:
- Cardiology
- Cardiovascular Research
- Interventional Cardiology
Background:
- Myocardial infarction (MI) is characterized by oxygen deprivation in the heart muscle.
- Early reperfusion is a key strategy for limiting infarct size and preserving cardiac function.
Purpose of the Study:
- To evaluate the efficacy of early reperfusion therapy in reducing infarct size and improving functional outcomes.
- To identify factors influencing the success of thrombolytic therapy and patient prognosis.
Main Methods:
- Assessment of global ejection fraction via angiography and gated blood pool imaging.
- Radioisotope perfusion imaging to quantify infarct size reduction.
- Analysis of patient outcomes based on thrombolysis success, creatine kinase levels, and collateral vessel presence.
Main Results:
- Thrombolytic therapy demonstrated efficacy through improved ejection fraction and reduced perfusion defects.
- Shorter ischemic periods and greater collateral circulation correlated with less ischemic damage in successful thrombolysis cases.
- Combination therapy (intravenous and intracoronary streptokinase) shortened ischemic times compared to monotherapy.
Conclusions:
- Early reperfusion, particularly within 3-5 hours, is recommended to minimize myocardial damage.
- Immediate revascularization after reperfusion can reduce mortality in patients with reocclusion or severe stenosis.
- Successful reperfusion offers significant benefits for specific patient subgroups, including those with prior MI or extensive perfusion defects.
Abstract:
The most critical substrate lacking in infarcting myocardium is oxygen and early reperfusion would appear to be the most promising approach to infarct reduction. The efficacy of thrombolytic therapy has been shown by an increase in the global ejection fraction assessed by angiography or gated blood pool techniques and also by a decrease of almost 50% in the radioisotope perfusion defect after 3 to 4 weeks. Functional results in a group of patients subdivided according to success of thrombolysis and plasma creatine kinase levels showed that, among patients with successful thrombolysis, those with the least ischemic damage had experienced shorter ischemic periods and had significantly more collateral vessels supplying the infarcting area. It is recommended that the ischemic period should not extend beyond 3 to 5 hours before therapy is begun. The combination of intravenous streptokinase followed by intracoronary streptokinase was found to lead to a significant shortening of the ischemic period when compared with intracoronary streptokinase alone. Reocclusion of the infarct vessel has been shown to occur in 10% to 30% of patients after successful reperfusion, especially in arteries with severe residual stenosis, but immediate revascularization carried out after reperfusion in such patients can bring about a substantial decrease in the 1 year mortality rate. Successful reperfusion showed particular benefit in patients with previous myocardial infarction in another area, in patients with large left ventricular perfusion defects and in patients with predominantly right ventricular infarction.